US biotechs to start parallel approvals in China

Minzhang Chen, chief executive of WuXi STA, provides an Expert View on the opening up of the world's second largest pharma market.

MAH has opened new opportunities for biotechs to access dual markets

It is no secret that, for any biotech, one of the primary focus points is how quickly they can get through milestones, and ultimately reach patients through commercial launch. In fact, for many US biotechs in particular, the sole focus of their attention has been how to get US Food and Drug Administration (FDA) approval and access to the lucrative US healthcare economy – with alternative markets simply an afterthought for post-commercial launch.